Evidence map›Paper›PMID 40935645›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2025

[A Case of Endometrial Metastasis in Lung Adenocarcinoma 
after EGFR-TKIs Treatment Failure and Literature Review].

Fangqian Shen, Zuling Hu, Hua Yang, Puyu Liu, Yuju Bai, Jianguo Zhou, Hu Ma

Abstract readCase ReportsReviewEnglish Abstract
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fangqian Shen *Department of Thoracic Oncology, 
The Second Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China.
Zuling Hu *Department of Abdominal Oncology, 
The Second Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China.
Hua YangDepartment of Pathology, 
The Second Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China.
Puyu LiuDepartment of Pathology, 
The Second Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China.
Yuju BaiDepartment of Thoracic Oncology, 
The Second Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China.
Jianguo ZhouDepartment of Thoracic Oncology, 
The Second Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China.
Hu MaDepartment of Thoracic Oncology, 
The Second Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The incidence and mortality rates of lung cancer remain high, making it the leading cause of cancer-related deaths. In women, the predominant histological subtype is lung adenocarcinoma, commonly associated with epidermal growth factor receptor (EGFR) mutations, and EGFR-tyrosine kinase inhibitors (EGFR-TKIs) can significantly improve patient prognosis. Metastasis of primary lung cancer to the endometrium is extremely rare and is often misdiagnosed as a primary reproductive system tumor, and its occurrence indicates poor prognosis. This article reports a case of an advanced lung adenocarcinoma patient with EGFR mutation, who developed abnormal vaginal bleeding after EGFR-TKIs treatment failure, and biopsy confirmed endometrial metastasis. A review of similar cases is also presented.
.

Indexed as

AdenocarcinomaEndometrial NeoplasmsLung NeoplasmsProtein Kinase InhibitorsAdenocarcinoma of LungErbB ReceptorsFemaleHumansMiddle AgedTreatment FailureEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsEGFR-TKIsEndometrial neoplasmImmunohistochemistryLung neoplasmsTumor metastasis

Identifiers

PMID40935645
PMCPMC12438716

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.